ZNTL
New analyst love, same old biotech roller coaster
William Blair kicked off coverage of Zentalis Pharmaceuticals with an Outperform rating, betting that the company’s lead cancer drug, azenosertib, could become a serious player in platinum-resistant ovarian cancer. Translation: one analyst looked at the data and basically said, “This might be more than just a science fair project.”
The bull case: azenosertib could be a big deal
The firm’s optimism centers on azenosertib, an oral WEE1 inhibitor being studied in Cyclin E1-positive platinum-resistant ovarian cancer. William Blair says the Phase 2 DENALI trial is the key near-term catalyst, with top-line results expected in the first half of 2027.
If the data cooperate, the company could chase accelerated approval and get a first-mover edge in a biomarker-defined slice of the market. That matters because biotech valuations can go from “meh” to “maybe buy the yacht” pretty fast when investors sniff a credible approval path.
Big numbers, bigger biotech drama
William Blair pegged azenosertib’s peak worldwide sales at about $1.3 billion, with a risk-adjusted value of $8.23 per share including net cash. The firm also pointed to AbbVie’s Elahere as proof that targeted ovarian cancer drugs can gain traction, while noting competition from Incyte and AstraZeneca is still lurking in the background.
- AbbVie is the poster child for biomarker-driven demand
- AstraZeneca is the cautionary tale after its WEE1 inhibitor got discontinued
- Incyte is developing a competing program of its own
The catch: biotech still loves a plot twist
This is still very much a show-me story. Zentalis has cash to keep the lights on for a while, but William Blair said the company will likely need more capital down the road. And if DENALI underwhelms, the accelerated-approval dream could slip and investors may have to wait for the Phase 3 ASPENOVA readout instead.
Big picture: the Street just got louder about Zentalis, but the stock now has to prove the science can keep pace with the hype.